Could an arthritis drug ease depression in Ex-Football players?
NCT ID NCT07608796
First seen Jun 13, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This study tests whether baricitinib, an anti-inflammatory drug, can improve depression and cognitive symptoms in 30 male former football players aged 40-55 with at least 10 years of play. Participants take the drug every other week for 6 weeks, and researchers use brain scans and motivation tasks to measure changes. The goal is to understand how inflammation affects these symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE SYMPTOMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory Clinic, Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Emory School Of Medicine
Atlanta, Georgia, 30322, United States
-
Emory University
Atlanta, Georgia, 30329, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Baricitinib (Olumiant), an oral drug that blocks inflammation
What this could lead to
If it works, this could point toward a new treatment for depression and cognitive issues linked to inflammation in former football players.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Baricitinib has side effects like increased infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.